深海潛艇 wrote:
但是連三期試驗都沒做的疫苗不關他吹噓得多厲害都是直接略過的選擇
另一個要注意的是 三期實驗 事實上所費不貲
一個藥品 三期實驗 花的錢約是1/3-1/2
而且 如果沒有所謂的EUA
時間可能拉長到三年 甚至於最後仍不得通過的窘境
殲二十 wrote:
科興用第1種標準，所以防護力僅得50%；歐美用第2種標準，防護力看起來就高很多。
但防重症與死亡，科興絕不低於歐美的四支，已經有不少國家發出科興防重症防死亡效果優異的報告。
Ninja nerd有解釋過，基本上都是第一種標準，防感染，也就是去做PCR看看有沒有中獎
防重症與死亡都說是很高，接近100%，AZ當初的報告也就是100%防重症
不過現在已經有對抗變種病毒的實例了，防重症在「預期上」也是很高，不過就沒有100%了
還是有很少部份打過兩劑疫苗的住院或是死亡
The study found that, for the period from 5 April to 16 May:
- the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the B.1.617.2 variant 2 weeks after the second dose, compared to 93% effectiveness against the B.1.1.7 variant
- 2 doses of the AstraZeneca vaccine were 60% effective against symptomatic disease from the B.1.617.2 variant compared to 66% effectiveness against the B.1.1.7 variant
- both vaccines were 33% effective against symptomatic disease from B.1.617.2, 3 weeks after the first dose compared to around 50% effectiveness against the B.1.1.7 variant
As with other variants, even higher levels of effectiveness are expected against hospitalisation and death. There are currently insufficient cases and follow-up periods to estimate vaccine effectiveness against severe outcomes from the B.1.617.2 variant. PHE will continue to evaluate this over the coming weeks.
與其他變體一樣，預計對住院和死亡的有效性甚至更高。 目前沒有足夠的病例和隨訪期來估計疫苗對 B.1.617.2 變體嚴重後果的有效性。 PHE 將在未來幾週內繼續對此進行評估。
economic wrote:
技術路線略有不同
這開發時就考慮到不是那樣低溫儲藏和運輸
能成功會對整體成本很有幫助
可惜沒成
歐盟還是對他們抱有希望，要等整體的評估
他們也預購很多劑了
European regulator EMA says it won't set 50% efficacy threshold for COVID shots
The European Medicines Agency (EMA) said on Thursday it would not impose a 50% efficacy threshold for COVID-19 vaccines, adding full trial data was necessary for it to make a sound assessment on the benefits and risks of a shot.
CureVac crashes after crucial COVID-19 vaccine trial disappoints
Franz-Werner Haas, CureVac’s chief executive, said in an interview with the New York Times that the company still plans to apply for approval from the European Medicines Agency (EMA).
Under CureVac’s only major supply deal for the product tested in the trial, the European Union in November secured up to 405 million doses of the vaccine, of which 180 million are optional.
In a bet on CureVac’s technology, Britain in February placed a conditional 50 million dose order on yet-to-be-developed vaccines that build on the product tested in the trial.
內文搜尋
從 APP 打開
X